Naltrekson: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
Mr. Ibrahem (bicara | kontrib) Fix references, Expend infobox mdwiki.toolforge.org. Tag: halaman dengan galat kutipan |
Tidak ada ringkasan suntingan |
||
Baris 48:
<!-- Pharmacokinetic data -->
| bioavailability = 5–60%<ref name="pmid2836152">{{cite journal |last1=Gonzalez |first1=JP |last2=Brogden |first2=RN |title=Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. |journal=Drugs |date=Maret 1988 |volume=35 |issue=3 |pages=192-213 |doi=10.2165/00003495-198835030-00002 |pmid=2836152}}</ref><ref name="pmid19537999">{{cite journal |last1=Lee |first1=MW |last2=Fujioka |first2=K |title=Naltrexone for the treatment of obesity: review and update. |journal=Expert opinion on pharmacotherapy |date=Agustus 2009 |volume=10 |issue=11 |pages=1841-5 |doi=10.1517/14656560903048959 |pmid=19537999}}</ref>
| protein_bound = 20%<ref name="pmid2836152" /><ref name="ReviaLabel" />
| metabolism = [[Liver]] (non-[[cytochrome P450|CYP450]])<ref name="SevarinoKosten2009">{{cite book | veditors = Dean RL, Bilsky EJ, Negus SS | title = Opiate Receptors and Antagonists | vauthors = Sevarino KA, Kosten TR | chapter = Naltrexone for Initiation and Maintenance of Opiate Abstinence | date = 2009 | pages = 227–245 | publisher = Humana Press | doi = 10.1007/978-1-59745-197-0_12 | isbn = 978-1-58829-881-2| url = }}</ref>
| |||